Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not C-RAF-1 protein

International Journal of Cancer

Volumn 67, Issue 2, 1996, Pages 224-231

  Warenius, Hilmar M ^a   Seabra, Laurence A ^a   Maw, Paula ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; RAF PROTEIN;

ARTICLE; CANCER CELL; CHEMOSENSITIVITY; CROSS LINKING; DNA DAMAGE; DOSE RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; IONIZING RADIATION; MALIGNANT TRANSFORMATION; ONCOGENE; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CISPLATIN; CYCLIN D1; CYCLINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; RADIATION-SENSITIZING AGENTS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0029810919     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960717)67:2<224::AID-IJC13>3.0.CO;2-B     Document Type: Article

References (30)

1. BASHAM, C., MILLS, J., DOUPLES, E.B. and ROBERTS, J.J., The independent action of radiation and cisplatin on the survival or recovery of human normal or tumour cells in vitro or in vivo. Int. J. Rad. Biol., 55, 807-820 (1989).
2. BASU, A. and LAZO, J.S., Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin 1. Cancer Res., 52, 3119-3124 (1992).
3. BRITTEN, R.A. and WARENIUS, H.M., De novo cisplatinum resistance does not influence cellular radiosensitivity. Europ. J. Cancer, 29A, 1315-1320 (1993).
4. BUCKLEY, M.F., SWEENEY, K.J., HAMILTON, J.A., SINI, R.L., MANNING, D.L., NICHOLSON, R.I., DEFAZIO, A., WATTS, C.K., MUSGROVE, E.A. and SUTHERLAND, R.L., Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8, 2127-2133 (1993).
5. BURT, R.K., GARFIELD, S., JOHNSON, K. and THORGEIRSSON, S.S., Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals. Carcinogenesis, 9, 2329-2332 (1988).
6. DAKIS, J.I., LU, R.Y., FACCHINI, L.M., MARHIN, W.W. and PENN, L.J.Z., Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene, 9, 3635-3645 (1994).
7. FILMUS, J., ROBLES, A.I., SKI, W., WONG, M.J., COLOMBO, L.L. and CONTI, C.J., Induction of cyclin D1 overexpression by activated ras. Oncogene, 9, 3627-3633 (1994).
8. FRAVAL, H.N.A. and ROBERTS, J.J., Excision repair of cis-diamminedi- chloroplatinum (II)-induced damage to DNA of Chinese hamster cells. Cancer Res., 39, 1793-1797 (1979).
9. FUJIKANE, T., SHIMIZU, T., TSUJI, T., ISHIDA, S., OHSAKI, Y. and ONODERA, S., Flow cytometric analysis of the kinetic effects of cisplatin on lung cancer cells. Cytometry, 10, 788-795 (1989).
10. GATELY, D.P. and HOWELL, S.B., Cellular accumulation of the anticancer agent cisplatin: a review. Brit. J. Cancer, 67, 1171-1176 (1993).
11. GONG, J., ARDELT, B., TRAGANOS, F. and DARZYNKIEWICZ, Z., Unscheduled expression of cyclin B1 and cyclin E in several leukaemic and solid tumour cell lines. Cancer Res., 54, 4285-4288 (1994).
12. GRANT, S., TRAYLOR, R., PETTIT, G.R. and LIN, P.S., Lineage-specific potentiation of the in vitro radioprotective effects of the GM-CSF/IL3 fusion protein PIXY 321 towards normal human bone marrow progenitors by bryostatin-1. Cytokine, 5, 490-497 (1993).
13. HALLAHAN, D.E., VIRUDACHALAM, S., SCHWARTZ, J.L., PANJE, N., MUSTAFI, R. and WEICHSELBAUM, R.R., Inhibition of protein kinases sensitizes human tumor cells to ionising radiation. Rad. Res., 129, 345-350 (1992).
14. HAN, K.H.E., SGAMBATO, A., JIANG, W., ZHANG, Y.J., SANTELLA, R.M., DOKI, Y., CACACE, A.M., SCHIEREN, J. and WEINSTEIN, I.B., Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene, 10, 953-961 (1995).
15. ISONISHI, S., HOM, D.K., EASTMAN, A. and HOWELL, S.B., Enhancement of sensitivity to platinum (II)-containing drugs by 12-O- tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line. Brit. J. Cancer, 69, 217-221 (1994).
16. KALECHMAN, Y., ALBECK MAND and TREDNI, B., In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin. Cell. Immunol., 143, 143-153 (1992).
17. KOLCH, W., HEIDECKER, G., KOCHS, G., HUMMEL, R., VAHIDI, H., MISCHAK, H., FINKENZELLER, G., MARME, D. and RAPP, U.R., Protein kinase C alpha activates RAF-1 by direct phophorylation. Nature (Lond.), 364, 249-252 (1993).
18. KONDO, S., BARNETT, G.H., HARA, H., MORIMURA, T. and TAKEUCHI, J., MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogens, 10, 2001-2006 (1995).
19. MELLISH, K.J., KELLAND, L.R. and HARRAP, K.R., In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Brit. J. Cancer, 68, 240-250 (1993).
20. 2 block induced by ionising radiation. Cancer Res., 51, 5113-5117 (1991).
21. NAGASAWA, H. and LITTLE, J.B., Comparison of the kinetics of X-ray induced cell killing in normal human, ataxia-telangiectasia and hereditary retinoblastoma fibroblasts. Mutation Res., 109, 297-308 (1983).
22. NIIMI, S., NAKAGAWA, K., YOKOTA, J., TSUNOKAWA, Y., NISHIO, K., TERASHIMA, Y., SHIBUYA, M., TERADA, M. and SAIJO, N., Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Brit. J. Cancer, 63, 237-241 (1991).
23. NISHIKAWA, K., ROSENBLUM, M.G., NEWMAN, R.A., PANDITA, T.K., HITTELMAN, W.N. and DONATO, N.J., Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. Cancer Res., 52, 4758-4765 (1992).
24. SANCHEZ-PRIETO, R., VARGAS, J.A., CARNERO, A., MARCHETTI, E., ROMERO, J., DURANTEZ, A., LACAL, J.C. and RAMON-Y-CAJAL, S., Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes. Int. J. Cancer, 60, 235-243 (1995).
25. SKLAR, M.D. and PROCHOWNIK, E.V., Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res., 51, 2118-2123 (1991).
26. 2 arrest and DNA double-strand breaks. Cancer Res., 48, 4484-4488 (1988).
27. THIEBAUT, F., ENNS, R. and HOWELL, S.B., Cisplatin sensitivity correlates with its ability to cause cell cycle arrest via a wee 1 kinase-dependent pathway in Schizosaccharomyces pombe. J. cell. Physiol., 159, 506-514 (1994).
28. +) fast neutrons and 4 MeV photons. Radioth. Oncol., 30, 83-89 (1994a).
29. WARENIUS, H.M., BROWNING, P.G.W., BRITTEN, R.A., PEACOCK, J.A. and RAPP, U.R., C-raf-1 proto-oncogene expression relates to radiosensitivity rather than radioresistance. Europ. J. Cancer, 30A, 369-375 (1994b).
30. XIONG, Y., ZHANG, H. and BEACH, D., Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev., 7, 1572-1583 (1993).